Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo

References

• MinottiGMennaPSalvatorelliECairoGGianniLAnthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityPharmacol Rev200456218522915169927
   PubMed Web of Science ®Google Scholar
• KalenderYYelMKalenderSDoxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechinToxicology20052091394515725512
   PubMed Web of Science ®Google Scholar
• YilmazSAtessahinASahnaEKarahanIOzerSProtective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicityToxicology20062182–316417116325981
   PubMed Web of Science ®Google Scholar
• MonsuezJJCharniotJCVignatNArtigouJYCardiac side-effects of cancer chemotherapyInt J Cardiol2010144131520399520
   PubMed Web of Science ®Google Scholar
• OctaviaYTocchettiCGGabrielsonKLJanssensSCrijnsHJMoensALDoxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategiesJ Mol Cell Cardiol20125261213122522465037
   PubMed Web of Science ®Google Scholar
• PreobrazhenskayaMNTevyashovaANOlsufyevaENHuangKHuangHSecond generation drugs-derivatives of natural antitumor anthracycline antibiotics daunorubicin, doxorubicin and carminomycinJ Med Sci2006264119
   Google Scholar
• PetrioliRFiaschiAIFranciniEPascucciAFranciniGThe role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancerCancer Treat Rev200834871071818620815
   PubMed Web of Science ®Google Scholar
• KratzFDOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trialsExpert Opin Investig Drugs2007166855866
   PubMed Web of Science ®Google Scholar
• KaminskasLMMcLeodVMKellyBDA comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systemsNanomedicine20128110311121704192
   PubMed Web of Science ®Google Scholar
• BaekSELeeKHParkYSRNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivoJ Control Release201419623424225450401
   PubMed Web of Science ®Google Scholar
• MaengJHLeeDHJungKHMultifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancerBiomaterials201031184995500620347138
   PubMed Web of Science ®Google Scholar
• MinatiLAntoniniVTorrengoSSustained in vitro release and cell uptake of doxorubicin adsorbed onto gold nanoparticles and covered by a polyelectrolyte complex layerInt J Pharm20124381–2455222959992
   PubMedGoogle Scholar
• ParkHTsutsumiHMiharaHCell-selective intracellular drug delivery using doxorubicin and α-helical peptides conjugated to gold nanoparticlesBiomaterials201435103480348724439396
   PubMed Web of Science ®Google Scholar
• PercheFPatelNRTorchilinVPAccumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid modelJ Control Release201216419510222974689
   PubMed Web of Science ®Google Scholar
• BaeSMaKKimTHDoxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor typesBiomaterials20123351536154622118776
   PubMed Web of Science ®Google Scholar
• BarenholzYDoxil® – the first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• ElzoghbyAOSamyWMElgindyNAAlbumin-based nanoparticles as potential controlled release drug delivery systemsJ Control Release2012157216818221839127
   PubMed Web of Science ®Google Scholar
• KratzFA clinical update of using albumin as a drug vehicle – a commentaryJ Control Release201419033133624637463
   PubMed Web of Science ®Google Scholar
• BharaliDJKhalilMGurbuzMSimoneTMMousaSANanoparticles and cancer therapy: a concise review with emphasis on dendrimersInt J Nanomedicine200941719421366
   PubMed Web of Science ®Google Scholar
• SocinskiMALangerCJOkamotoISafety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerAnn Oncol201324231432123123509
   PubMed Web of Science ®Google Scholar
• MaWWHidalgoMThe winning formulation: the development of paclitaxel in pancreatic cancerClin Cancer Res201319205572557923918602
   PubMed Web of Science ®Google Scholar
• BlasiFCarmelietPuPAR: a versatile signalling orchestratorNat Rev Mol Cell Biol200231293294312461559
   PubMed Web of Science ®Google Scholar
• SmithHWMarshallCJRegulation of cell signalling by uPARNat Rev Mol Cell Biol2010111233620027185
   PubMed Web of Science ®Google Scholar
• YangLSajjaHKCaoZuPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detectionTheranostics20134110611824396518
   PubMed Web of Science ®Google Scholar
• PerssonMKjaerAUrokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applicationsClin Physiol Funct Imaging201333532933723701192
   PubMed Web of Science ®Google Scholar
• PerssonMMadsenJØstergaardSQuantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasionJ Nucl Med201253113814522213823
   PubMed Web of Science ®Google Scholar
• HuaiQMazarAPKuoAStructure of human urokinase plasminogen activator in complex with its receptorScience2006311576165665916456079
   PubMed Web of Science ®Google Scholar
• HuaiQZhouALinLCrystal structures of two human vitronectin, urokinase and urokinase receptor complexesNat Struct Mol Biol200815442242318376415
   PubMed Web of Science ®Google Scholar
• PlougMEllisVStructure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxinsFEBS Lett199434921631688050560
   PubMed Web of Science ®Google Scholar
• LiRZhengKHuPA novel tumor targeting drug carrier for optical imaging and therapyTheranostics20144664265924723985
   PubMed Web of Science ®Google Scholar
• YangLPengXHWangYAReceptor-targeted nanoparticles for in vivo imaging of breast cancerClin Cancer Res200915144722473219584158
   PubMed Web of Science ®Google Scholar
• OommenOPGarousiJSloffMVargheseOPTailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approachMacromol Biosci201414332733324130147
   PubMed Web of Science ®Google Scholar
• GrabarekJBZyzyńskaKSaizNDifferential plasticity of epiblast and primitive endoderm precursors within the ICM of the early mouse embryoDevelopment2012139112913922096072
   PubMed Web of Science ®Google Scholar
• AgudeloDBourassaPBruneauJBérubéGAsselinETajmir-RiahiHAProbing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albuminsPLoS One201278e4381422937101
   PubMed Web of Science ®Google Scholar
• FülöpZGrefRLoftssonTA permeation method for detection of self-aggregation of doxorubicin in aqueous environmentInt J Pharm2013454155956123850794
   PubMed Web of Science ®Google Scholar
• PetersTJrAll About Albumin: Biochemistry, Genetics, and Medical ApplicationsSan Diego, USAAcademic Press1996
   Google Scholar
• Abi-HabibRJSinghRLiuSBuggeTHLepplaSHFrankelAEA urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell typesMol Cancer Ther20065102556256217041100
   PubMed Web of Science ®Google Scholar
• YardleyDAnab-Paclitaxel mechanisms of action and deliveryJ Control Release2013170336537223770008
   PubMed Web of Science ®Google Scholar
• MarzoliniCPausEBuclinTKimRBPolymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClin Pharmacol Ther2004751133314749689
   PubMed Web of Science ®Google Scholar
• AllerSGYuJWardAStructure of P-glycoprotein reveals a molecular basis for poly-specific drug bindingScience200932359221718172219325113
   PubMed Web of Science ®Google Scholar
• HuangYSadéeWMembrane transporters and channels in chemoresistance and -sensitivity of tumor cellsCancer Lett2006239216818216169662
   PubMed Web of Science ®Google Scholar
• O’HalloranTVAhnRHankinsPSwindellEMazarAPThe many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single targetTheranostics20133749650623843897
   PubMed Web of Science ®Google Scholar
• BarefordLMSwaanPWEndocytic mechanisms for targeted drug deliveryAdv Drug Deliv Rev200759874875817659804
   PubMed Web of Science ®Google Scholar
• HoJAFanNCJouAFWuLCSunTPMonitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug deliveryTalanta20129968368822967611
   PubMed Web of Science ®Google Scholar
• HanMVakiliMRSoleymani AbyanehHMolaviOLaiRLavasanifarAMitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cellsMol Pharm20141182640264924811541
   PubMed Web of Science ®Google Scholar
• GolsteinPKroemerGCell death by necrosis: towards a molecular definitionTrends Biochem Sci2007321374317141506
   PubMed Web of Science ®Google Scholar
• FangJNakamuraHMaedaHThe EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdv Drug Deliv Rev201163313615120441782
   PubMed Web of Science ®Google Scholar
• MaedaHNakamuraHFangJThe EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivoAdv Drug Deliv Rev2013651717923088862
   PubMed Web of Science ®Google Scholar